ha-23

HA-23 is a Ca(2+)-channel blocker.

Lanopepden, also known as GSK-1322322 or GSK-322, is a potent and selective peptide deformylase inhibitor with good in vitro activity against bacteria associated with community-acquired pneumonia and skin infections. GSK1322322 had bactericidal activity against S. pneumoniae, H. influenzae, S. pyogenes, and S. aureus, demonstrating a ≥ 3-log(10) decrease in the number of CFU/ml at 4× MIC within 24 h in 29 of the 33 strains tested. GSK1322322 represents a valuable alternative therapy for the treatment of infectious diseases caused by drug-resistant pathogens.

Alpha-2-3,6-sialidase (BiNanH2), a sialyltransferase commonly utilized in biochemical research, catalyzes the transfer of α-2,3/2,6-sialyl from CMP-Neu5Ac to galactoside acceptors [1].

VF-57a (Compound 23) is an inhibitor of Influenza A virus (IAV) fusion. It exhibits potent antiviral activity against the real A/H1N1 virus, with EC50 values of 0.92 μM for the A/H1N1 PR8 strain and 0.31 μM for the A/H1N1 Virg09 strain. VF-57 significantly inhibits cell entry of HA-mediated A/H1N1 and A/H5N1 pseudoviruses and prevents HA refolding at pH 5.2. VF-57a is utilized in IAV infection research.